CM
NTLA icon

Capula Management’s Intellia Therapeutics NTLA Stock Holding History

Capula Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,187
Closed -$765K – 590
2024
Q2 		$765K Buy
+34,187
New +$814K 0.01% 206

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capula Management's NTLA Position: Q3 2024 in Review

Capula Management sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 34,187 shares — an estimated $765K sold.

Capula Management first reported a position in NTLA in Q2 2024 and held it in 1 quarter. The position peaked at $765K in Q2 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Capula Management reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Capula Management sold 34,187 Intellia Therapeutics shares in Q3 2024, an estimated $765K.
  • Capula Management first reported a position in Intellia Therapeutics in Q2 2024 and held it in 1 quarter.
  • Capula Management's Intellia Therapeutics position peaked at $765K in Q2 2024.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Capula Management's 13F filing for Q3 2024, filed 13 Nov 2024.